title: Enhancing radiation therapy for patients with glioblastoma.
abstract: Radiation therapy has been the foundation of therapy following maximal surgical resection in patients with newly diagnosed glioblastoma for decades and the primary therapy for unresected tumors. Using the standard approach with radiation and temozolomide, however, outcomes are poor, and glioblastoma remains an incurable disease with the majority of recurrences and progression within the radiation treatment field. As such, there is much interest in elucidating the mechanisms of resistance to radiation therapy and in developing novel approaches to overcoming this treatment resistance.
authors.affiliation: Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, 75 Francis Street, ASB1-L2, Boston, MA 02115, USA. bmalexander@lroc.harvard.edu
authors.forename: Brian M
authors.initials: BM
authors.lastname: Alexander
authors.forename: Keith L
authors.initials: KL
authors.lastname: Ligon
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005909:Glioblastoma / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D003606:Dacarbazine; D000077204:Temozolomide